Drugs / AIMSPRO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01228396 | May 2009 → May 2011 | secondary progressive multiple sclerosis | Daval International Limited | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIMSPRO | “Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection” NCT01228396 ↗ |
| Modality | Protein / enzyme biologic | “Hyperimmune caprine serum against HIV lysate” NCT01228396 ↗ |
| Route | Subcutaneous | “1.0ml solution for subcutaneous injection” NCT01228396 ↗ |